Published in Blood Weekly, August 29th, 2002
Current methods for identifying and monitoring patients' B-cell lineage tumors such as myeloma rely on electrophoresis-based testing for Bence-Jones (BJ) proteins, which are homogeneous populations of k or l free light chain (FLC) molecules produced by malignant B-cell clones. This type of testing, usually performed on urine specimens, is expensive, time-consuming and sometimes inaccurate.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.